CBRNE - Botulism

Updated: Feb 23, 2023
Author: Peter P Taillac, MD; Chief Editor: Duane C Caneva, MD, MSc 


Practice Essentials

Botulism is a paralytic disease caused by the neurotoxins of Clostridium botulinum and, in rare cases, C butyricum and C baratii. These gram-positive spore-forming anaerobes can be found in soil samples and marine sediments throughout the world. With a lethal dose to humans of less than 1 mcg, botulinum toxins are the most poisonous substances known and pose a great threat as an agent of biological warfare. It is estimated that one gram of aerosolized botulism toxin has the potential to contain 1.5 lethal doses. Botulinum toxin is classified by the Centers for Disease Control and Prevention (CDC) as one of the six highest-risk threat agents for bioterrorism because of the high lethality, ease of production and transport, and need for prolonged intensive care treatment.


Six forms of botulism are now described, depending on the route of acquisition, as follows:

  • Food-borne botulism
  • Wound botulism
  • Infant botulism
  • Adult intestinal colonization botulism
  • Injection-related botulism
  • Inhalational botulism

Food-borne botulism follows the ingestion of preformed toxin in foods that have not been canned or preserved properly.

Wound botulism, caused by systemic spread of toxin produced by organisms inhabiting wounds, is associated with trauma, surgery, subcutaneous heroin injection, and sinusitis from intranasal cocaine abuse.

Infant botulism results from intestinal colonization of organisms in infants younger than 1 year. In this age group, normal intestinal flora may not have developed to the degree that prevents colonization by these organisms in healthy adults.

Adult intestinal colonization botulism is similar in pathogenesis to infant botulism. This form occurs in older children and adults with abnormal intestinal function or anatomy, such as colitis, intestinal bypass procedures, or other conditions that may create local or widespread disruption in the normal intestinal flora.

Injection-related botulism is a result of inadvertent misadventures with injection of therapeutic pharmaceutical botulinum toxin.

Inhalational botulism has recently been described. To date, the only human cases have been the result of inadvertent inhalation of toxin by laboratory workers. However, aerosolization and inhalation of botulinum toxin is considered a likely method for poison delivery in a bioterrorist attack.

Differences in antigenicity among the toxins produced by different strains of botulism-causing organisms allow for separation of the organisms into 7 distinct types (A-G). Types A, B, and E are the toxins most often responsible for disease in humans, whereas types C and D only cause disease in other animals (eg, nonhuman mammals, birds, fish). In rare instances, a single strain of organism may produce 2 toxins.

As alluded to earlier, clostridia other than C botulinum have been associated with a handful of cases of botulism. These include reports of food-borne and infant botulism associated with type E toxin produced by C butyricum. Adult and infant intestinal colonization botulism, associated with type F toxin-producing C baratii, has been documented.

In 2014, a new strain of C botulinum was isolated from an infant with botulism, which elaborated 2 toxinotypes: B and a novel toxin designated “H.”[1]  In 2016, the CDC reported that additional genetic studies revealed type H to be a hybrid toxin composed of elements of toxinotypes A and F, and established that the type A antitoxin neutralized toxin type H.[2]

In addition, strains of C botulinum have been classified into the following four groups based on their phenotypic characteristics and DNA homology:

  • Group I organisms are proteolytic and produce toxins A, B, or F
  • Group II is nonproteolytic and can make toxins B, E, or F
  • Group III organisms produce toxins C or D
  • Group IV organisms, now identified as  C argentinense, produce toxin type G, which has not been shown to cause neuroparalytic illness but has been associated with sudden death in Switzerland

For more information, see Medscape's Bioterrorism Resource Center.


Investigations of Clostridium neurotoxin as a biological weapon have been carried out by various nations. The Japanese in World War II carried out human experiments on prisoners in Manchuria. Also in World War II, the British secretly used a botulism-impregnated grenade in the assassination of a German Gestapo officer.

The United States studied botulinum toxin as a military bioweapon until President Nixon signed the Biological and Toxin Weapons Convention in 1972, ending all US biotoxin weapons research. Iraq and the Soviet Union stockpiled neurotoxin, with Iraq admitting to weaponizing thousands of liters of toxin in warheads after the 1991 Gulf War. An attempt at terrorist use of Clostridium toxin in the early 1990s by the Japanese Aum Shinrikyo cult against American military targets was unsuccessful.

The term botulus is derived from the Latin word for "sausage." An outbreak of clostridial "sausage poisoning" in Europe in the late 1700s was responsible for many deaths. A German physician, Dr. Justinus Kerner, published the first case descriptions of botulism in 1822, with experiments conducted on himself and laboratory animals. Investigation and confirmation of poor canning practices as the cause of outbreaks of food-borne botulism occurred in the 1920s.


C botulinum is distributed widely throughout the environment and can be found in soil, freshwater and saltwater sediments, household dust, and on the surfaces of many foods. The toxins produced are cytoplasmic proteins (mass = 150 kd) released as cells lyse. The spores will germinate and bacterial growth and toxin elaboration occur in an anaerobic, low-salt, low-acid environment. The toxin is destroyed by heating to 85 C for 5 minutes and the spores are inactivated by heating to 121° C under pressure of 15-20 lb/in2 for at least 20 minutes.

Although the mode of entry of toxin may differ between the different forms of diseases, once the toxin enters the bloodstream, it acts in a similar manner to produce the clinical symptoms. The toxin binds to receptors on presynaptic terminals of cholinergic synapses, is internalized into vesicles, and then is translocated to the cytosol. In the cytosol, the toxin mediates the proteolysis of components of the calcium-induced exocytosis apparatus (the SNARE proteins) to interfere with acetylcholine release. Blockade of neurotransmitter release at the terminal is permanent, and recovery only occurs when the axon sprouts a new terminal to replace the toxin-damaged one. This process is shown in the illustration below.

Courtesy of Arnon SS, et al. Botulinum toxin as a Courtesy of Arnon SS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001 Apr 25;285:1059.

The effects of the toxin are limited to blockade of peripheral cholinergic nerve terminals, including those at neuromuscular junctions, postganglionic parasympathetic nerve endings, and peripheral ganglia. This blockade produces a characteristic bilateral descending paralysis of the muscles innervated by cranial, spinal, and cholinergic autonomic nerves but no impairment of adrenergic or sensory nerves, and no central nervous impairment. The classic syndrome of botulism is a symmetrical, descending motor paralysis in an alert patient, with no sensory deficits.


In 2021, the American Association of Poison Control Centers (AAPCC) Toxic Exposure Surveillance System reported 368 single exposures to botulism and one death. The majority of cases (61%) were in children less than 6 years old.[3]  

Food-borne botulism, the first form of the disease to be identified, is responsible for approximately 1000 reported annual cases worldwide. While European cases most commonly are associated with type B contamination of home-processed meats, Alaskan, Canadian, and Japanese outbreaks often involve type E toxin in preserved seafood. Chinese cases involve type A toxin in home-processed bean products. Cases in Thailand have been associated with ingestion of home-preserved bamboo shoots.[4]

Most cases in the continental US are associated with home-canned vegetable products such as asparagus, green beans, and peppers. Of the average 20 to 30 food-borne US cases yearly, approximately 60% are type A, 18% type B, and 22% type E.  Alaska, California, Michigan, Washington, New Mexico, Illinois, Oregon, and Colorado have the highest incidences of food-borne botulism. Between 1990 and 2000, Alaska accounted for 39% of the US cases.[5, 6, 7]

The toxin type most often responsible for food-borne illness corresponds well with the geographic distribution of the toxigenic species. Type A is most common west of the Mississippi, type B east of the Mississippi, and type E in Alaska. Toxin type A produces a more severe illness than type B, which in turn is more severe than type E.

By far, home-processed foods are responsible for most (94%) outbreaks of food-borne botulism in the continental US. In fact, of the 6% of outbreaks caused by mass-produced commercial foods, most cases were attributed to consumer mishandling of commercial products.

Infant botulism occurs in children younger than 1 year, with 95% of the cases occurring in patients younger than 6 months. Peak susceptibility is in the 2- to 4-month range. In the 16 years following its identification in 1976, 1134 cases of infant botulism have been recorded in the United States. With approximately 60 cases of infant botulism reported each year, it is now the most frequently occurring form of botulism. The disease is most common in the western part of the United States. One half of all annual cases are reported in California, where the frequency of the toxin responsible is distributed equally between types A and B.

While the toxin types of food-borne botulism seem to reflect the distribution of toxigenic strains in the environment, the frequency of type B toxin in infantile botulism is disproportionately high. Although the case-fatality ratio for infant botulism in the US is less than 2%, the disease is suspected to be responsible for up to 5% of sudden infant death syndrome cases in California.

Although the ingestion of honey has been identified as a strong risk factor for the disease, it is found in fewer than 20% of case histories (and only 5% of case histories in California in recent years).

Other risk factors that have been reported include infants with higher birth weights and mothers who were older and better educated than the general population. Another reported risk factor was a decreased frequency of bowel movements (< 1/d) for at least 2 months. Breastfeeding was associated with older age at onset of illness in type B cases.

Through 1992, only 1-3 cases of wound botulism were reported in the US each year. Two thirds of these cases were type A and almost one third were type B. One half of all cases were reported from California. In recent years, the number of reported cases of wound botulism has risen dramatically, with 11 cases in California in 1994 and 19 cases confirmed by the State Department of Health Services during the first 11 months of 1995. All but 1 of 40 cases reported in California, at this writing, involved drug abusers, many with subcutaneous injection or skin-popping of heroin.

Cases of adult colonization botulism have been increasingly reported in the literature. In some of these cases, C botulinum organisms, but no preformed toxin, could be found in foods the patients had ingested. These cases were associated with a prolonged latent period of up to 47 days postingestion before onset of symptoms. In one study, 2 of 4 patients had surgical alterations of the gastrointestinal tract that may have promoted colonization.[8]  Jejunoileal bypass, surgery of the small intestine, Crohn disease, inflammatory bowel disease, antimicrobial therapy, or foodborne botulism are among other reported factors predisposing adult patients for intestinal colonization.[9]

Only rare cases of injection-related botulism have been reported, despite the increasingly common use of botulinum neurotoxin in neurology, ophthalmology, and dermatology practices. The standard packaging mandated by the FDA contains doses that are well below the human toxic level.


Prognosis is generally good with early detection, early antitoxin administration, and intensive supportive therapy. 

For food-borne botulism, patients with an early onset of clinical symptoms (within 36 hours of toxin ingestion), index patients in food-borne cases, and patients older than 60 years generally have a longer clinical course than their counterparts.

Deaths occurring within the first 2 weeks of botulism are most often due to failure to recognize the severity of disease or from pulmonary or systemic infection. The average duration of respiratory support for those requiring mechanical ventilation is 6-8 weeks but may be as long as 7 months.

For food-borne botulism, severity of disease seems to be associated with toxin type. Intubation is required for 67% of patients with type A botulism, 52% of patients with type B, and 39% of patients with type E. In addition to being more likely to need ventilatory support, patients with type A botulism tend to see a physician earlier and have a longer course of illness than those with type B botulism. The case-fatality rate for type A botulism is 10%, twice that of type B.

Ventilatory and upper airway muscle strength, along with exercise performance, predominantly build within the first 12 weeks, and most patients are back to normal within 1 year with type A botulism. Dyspnea, fatigue, and decreased maximal workload are common 2 years after type B intoxication, although lung function tests have returned to normal.

The overall case-fatality rate is approximately 7-10%. For patients older than 60 years old, the fatality rate is approximately doubled. The mortality rate is lower for patients who receive prompt antitoxin compared with those with delayed treatment.

Infant botulism progresses for 1-2 weeks and stabilizes for 2-3 weeks before recovery begins. The average length of a hospital stay for infants is approximately 1 month, although excretion of toxin and organisms may continue for more than 3 months following discharge. The infant case-fatality rate (1.3%) is low compared to food-borne illness, but a 5% relapse rate is associated with infant botulism after apparent resolution of clinical symptoms.

The case-fatality rate of wound botulism is 10%, and survivors experience significant morbidity requiring prolonged medical care.[10]

The occurrence of an episode of botulism does not necessarily confer immunity toward subsequent episodes. Immunization in the form of a pentavalent toxoid is available, but it is used only for those in high-risk areas such as laboratory workers and certain military personnel. It requires yearly boosters to remain protective.




Although laboratory confirmation is necessary for a definitive diagnosis, clinical presentation, patient history, and physical examination (particularly neurologic exam) can be used as strong indicators for the presence of botulism. Due to the delay in laboratory confirmation and the necessity of treatment prior to the binding of the toxin to neurons, antitoxin should be empirically begun in patients with highly suggestive presentations.

Place special attention on eliciting a complete patient history, including the following:

  • History of foods eaten, and any ill contacts who ate the same foods.
  • History of intravenous drug abuse (especially "skin popping")
  • Recent surgery or trauma
  • Gastrointestinal problems or intestinal bypass surgery
  • Laparoscopic appendectomy [11] (one case report)

Physical Examination

Physical examination findings vary according to the form of botulism (ie, food borne, infant, wound).

Food-borne botulism

The Centers for Disease Control and Prevention (CDC) suggests attention to the following cardinal features:

  • Patient is afebrile unless another infection is present

  • Patient demonstrates symmetric neurologic symptoms

  • Patient remains responsive, with intact sensation (14% of patients report some paresthesias or decreased sensation)

  • Patient has a normal or slow heart rate in the absence of hypotension

  • Signs typically are not accompanied by sensory deficits, with the exception of blurred vision

The neurologic manifestations often have been described as a progressive, symmetric, descending weakness or paralysis that first affects muscles innervated by the cranial nerves, then progresses to involve muscles of the neck, arms, and legs; this occurs in an alert patient with intact sensorium and intact sensation

The typical progression of symptoms (in order of appearance) in a botulinum neurotoxin poisoning can be summarized by the Dozen D's: dry mouth, diplopia, dilated pupils, droopy eyes, droopy face, diminished gag reflex, dysphagia, dysarthria, dysphonia, difficulty lifting head, descending paralysis, and diaphragmatic paralysis.[12]

Respiratory difficulty arises from airway obstruction and diaphragmatic weakness. Diplopia, dysarthria, dry mouth, and generalized weakness are among the most common presenting symptoms. Other symptoms that have been associated with botulism include ptosis, dysphagia, sore throat, dysphonia, nystagmus, ataxia, paresthesias, paralytic ileus, severe constipation, urinary retention, and orthostatic hypotension.

Pupils are dilated or unreactive (ophthalmoplegia) in 50% of patients. Unless secondary complications such as respiratory failure develop, patients are alert and mental function is unimpaired

Sensory deficits only have been reported in isolated cases; neurologic symptoms may appear from 6 hours to 10 days after ingestion of toxin, with a median incubation period of 1 day

Nausea, vomiting, and diarrhea often precede or accompany neurologic manifestations; constipation typically follows after neurologic signs have appeared. GI symptoms are more prominent in food-borne botulism and much less pronounced in cases of wound botulism.

Infant botulism

The degree of involvement in this form of the disease can vary from asymptomatic to paralysis to sudden death.

A prominent and common sign of the disease is constipation (defined as 3 or more days without defecation). Other clinical features include listlessness, lethargy, difficulty in sucking and swallowing, hypotonia, weak cry, poor feeding, pooled oral secretions, generalized muscle weakness, and poor head control, which gives the infant a characteristic floppy appearance.

Neurologic findings include the following:

  • Ptosis
  • Ophthalmoplegia
  • Sluggish pupillary reaction to light
  • Flaccid expression
  • Dysphagia
  • Weak gag reflex
  • Poor anal sphincter tone

Respiratory failure occurs in approximately 50% of diagnosed patients.

The incubation period (between the time of spore ingestion and onset of symptoms) associated with infant botulism varies from 3-30 days.

Wound botulism

Patients often present with much of the same symptomatology that is observed in the food-borne form, including acute blurred vision, dysphagia, dysarthria, generalized weakness (with or without absence of deep tendon reflexes), and pupillary abnormalities.[13]  Gastrointestinal manifestations are absent.

The Clostridium- infected wound generally appears benign, without typical signs of infection (unless also infected by other bacteria, in which case a fever also may be present). In some cases, the wound is not apparent.

The average incubation period is 10 days.



Diagnostic Considerations

Other problems to be considered in the differential diagnosis include the following:

  • Congenital or autoimmune neuropathy or myopathy
  • Mushroom (muscarine) poisoning
  • Poliomyelitis
  • Tick paralysis

Differential Diagnoses



Laboratory Studies

For laboratory confirmation, before treatment with antitoxin, obtain 10-15 mL of serum, 25-50 g of feces, and possibly 25-50 mL of fluid from gastric aspiration. Collect and refrigerate similar quantities of suspected food samples for testing. In constipated patients, a gentle saline enema may be required to obtain fecal specimens.

Label each specimen container with the patient's name, specimen type, date of collection, and medications being received, and send it to a state health department-approved reference laboratory in insulated cold packs. Contact your local health department for specific instructions.

Confirmation of the organism and/or toxin and toxin typing is obtained in almost 75% of cases. Early cases are more likely to be diagnosed by toxin assay, whereas later ones are more likely to have a positive culture. Laboratory confirmation of toxin presence is via a mouse bioassay, and identification of the toxin type is performed by a mouse toxin neutralization test.

Food-borne botulism

For food-borne botulism, toxin is found in serum samples 39% of the time and in stools 24% of the time. Organisms are found in cultures of stool samples 55% of the time. Stool cultures generally are more sensitive than toxin detection for specimens obtained later (> 3 d postingestion) in the course of illness.

An experimental test strip has been developed that enables field detection of type A and B toxins in foods.[14] A cell-based assay that uses a fluorescence reporter construct expressed in a neuronal cell model to study toxin activity in situ was able to detect as little as 100 pM botulism A activity in living cells, and is being evaluated for use in food matrices.[15]

Infant botulism

In patients whom infant botulism is suspected, stools and enema fluids (with minimal water added to limit dilution of toxin) are the specimens of choice, as serum is only rarely toxin positive. One also may wish to culture possible sources of clostridia, such as honey or house dust.

Other botulism forms and laboratory tests

Wound botulism: Wound botulism may be identified by detection of toxin in serum or by culture of wound specimens.

Adult colonization botulism: Organisms may be detected in stool and toxin in serum for up to 119 days following the onset of symptoms.

New methods of detection: In vitro methods of detection, including polymerase chain reaction (PCR) – based detection of clostridial genes and enzyme-linked immunoassay (ELISA) identification of toxin, have been developed. However, these methods are not widely available outside of research institutions.



Emergency Department Care

Antitoxin should be administered as soon as the clinical diagnosis is established, as laboratory confirmation requires days. The early administration of antitoxin will not reverse the course of the intoxication but will prevent further progression of paralysis. This is the best method to prevent diaphragmatic involvement and the need for mechanical ventilation. Antitoxin can only bind neurotoxin free in the blood. Once in the neuron, it cannot be bound.

Food-borne botulism

Monitor asymptomatic individuals who have eaten food suspected of being contaminated for the appearance of neurologic signs and symptoms.

Enemas and cathartics or whole-bowel irrigation may be used (if no ileus is present) to purge the gut of toxin. If ingestion occurred within the past few hours, emetics or gastric lavage may aid in the removal of toxin.

In infant botulism, most cases progress to complete respiratory failure. Intubation is required for a median of 16-23 days. Tracheostomy usually is not required.

Pediatric nutritional support: Intravenous feeding (hyperalimentation) is discouraged because of its potential for secondary infection and because of the success with nasogastric or nasojejunal tube feeding.

Wound botulism

Wound botulism requires thorough debridement of the wound site, even if it appears to be healing well. Follow this by injection of 3% hydrogen peroxide to produce aerobic conditions. Hydrogen peroxide itself is not innocuous to tissues, and some have advocated using hyperbaric oxygen therapy if available.

Antitoxin may be injected directly into the wound site.

Urinary retention may require use of a catheter.

Respiratory concerns

In adults, botulism results in pulmonary complications in 81% of patients, with ventilatory failure in one third.

Monitor spirometry, pulse oximetry, and arterial blood gas measurements, with particular attention placed on serial measurements of maximal static inspiratory pressure and respiratory vital capacity to help in predicting respiratory failure.

Strongly consider intubation and mechanical ventilation when vital capacity is less than 30% of predicted (or < 12 mL/kg), particularly when absolute or relative hypercarbia and rapidly progressive paralysis with hypoxemia are evident.



Botulism is a notifiable disease in the United States. Medical care providers who suspect botulism in a patient should immediately call their state health department's emergency 24-hour telephone number. The state health department will contact the CDC to report suspected botulism cases, arrange for a clinical consultation by telephone and, if indicated, request release of botulinum antitoxin.

Other consultations may include the following:

  • Pulmonology for respiratory sequelae
  • Surgery for wound care
  • Infectious disease specialist for management issues


Inform the public about the hazards of improperly preserved or canned foods. Inform expectant mothers not to administer honey to infants.

There is no vaccine against botulinum toxin, although the antitoxin may induce host immunity to the toxin and therefore may be efficacious when used as a vaccine. A program for vaccination of workers at high risk was ended by the CDC in 2011.[16]



Guidelines Summary

In 2021, the Centers for Disease Control and Prevention (CDC) released guidelines for the diagnosis and treatment of botulism.[17]

Cinical Criteria Tool

The CDC guidelines include the following clinical criteria tool for early diagnosis of botulism in crisis and contingency settings[17] :

  • Afebrile (< 100.4°F [< 38°C])§
  • Acute onset of at least one of the following symptoms:
    • Blurred vision
    • Double vision
    • Difficulty speaking, including slurred speech
    • Any change in sound of voice, including hoarseness
    • Dysphagia, pooling of secretions, or drooling
    • Thick tongue
  • At least one of the following signs:
    • Ptosis
    • Extraocular palsy or fatigability (the latter manifested by inability to avert eyes from light shone repeatedly into eye [typically used in infants])
    • Facial paresis (manifested, for example, by loss of facial expression or pooling of secretions and in young children by poor feeding, poor suck on breast or pacifier, or fatigue while eating)
    • Fixed pupils
    • Descending paralysis, beginning with cranial nerves

The CDC recommends clinicians consider botulism when myasthenia gravis or Guillain-Barré syndrome are suspected and in a patient with unexplained symmetric cranial nerve palsies, with or without paresis of other muscles. Thorough, serial neurologic examinations should be conducted to detect the neurologic deficits of botulism and their progression.[17]

Ask patients about possible exposures to well-described sources of botulinum toxin, while keeping in mind that absence of such exposures does not exclude the possibility of botulism. Electrodiagnostic testing should be considered to assist in diagnosis of a suspected botulism case. When conducted and interpreted by experts, EMG, RNS, and NCSs can provide useful diagnostic data.[17]

If botulism is suspected, local or state health department’s emergency on-call staff  must be notified immediately to arrange an emergency expert clinical consultation and, when indicated, request botulinum antitoxin from CDC. Discuss specimen collection with the expert consultant from CDC or the local or state health department.[17]

Collect specimens for laboratory confirmation of the clinical diagnosis of botulism as soon as possible because toxin levels decrease over time. Obtain serum before botulinum antitoxin heptavalent (BAT) is administered. Store and transport specimens for botulism testing at refrigeration temperatures (36°F–46°F [2°C–8°C]); do not freeze.[17]

Monitoring Illness Progression

Because paralysis may result in respiratory compromise from upper airway collapse or respiratory muscle impairment, patients should be closely monitored.  Key CDC recommendations include the following[17] :

  • Frequent, serial neurologic examinations, with an emphasis on cranial nerve palsies, swallowing ability, respiratory status, and extremity strength should be conducted.
  • In settings of contingency and crisis standards of care, focus examinations on signs and symptoms of early onset. Consider brief, focused training in the emergency setting on the neurologic examination.
  • When possible, have the same health care provider conduct the serial neurologic and other examinations.
  • Adjust the frequency of neurologic and other examinations on the basis of signs and symptoms, with very frequent examinations for patients with rapid progression and for patients who have respiratory or bulbar symptoms but have not required intubation.
  • Institute frequent, serial monitoring of respiratory and bulbar function. 
  • Focus the respiratory examination on respiratory rate, lung field auscultation, and work of breathing, including use of accessory muscles of respiration, nasal flaring, and paradoxical breathing.
    • Obtain serial objective data through spirometry, EtCO2 monitoring, blood gas analysis, or other tests. Patients with facial weakness might not achieve an adequate seal around the spirometer mouthpiece and so might require a mask device. If spirometry is not available, consider using the sniff nasal inspiratory pressure or the single breath count test.
    • Consider respiratory status in the context of neurologic status because paralysis can alter signs typically associated with respiratory distress. 
  • Focus bulbar dysfunction examination on dysphagia, dysarthria, nasal voice, drooling, and impaired gag reflex. When feasible, consider assessing the patient’s swallowing ability to help determine whether the patient can safely consume liquids or solids.
  • Continuously monitor cardiac rhythm and frequently measure blood pressure.
  • Frequently monitor for urinary retention, constipation or ileus, dry mouth, and dry eyes.


Administer botulinum antitoxin to patients with suspected botulism as early as possible in the course of illness. The greatest benefit accrues to those who receive it within the first 2 days of illness onset.  Patients with suspected botulism should be treated with BAT regardless of underlying medical conditions or age, sex, or other demographic characteristics. Pregnant women with suspected foodborne botulism should be treated with BAT in the same manner as nonpregnant patients.[17]

The standard adult dose is one vial, administered by intravenous infusion. The pediatric dose is based on weight. Ensure that epinephrine and antihistamine treatments are available for all patients receiving BAT.[17]  

Patients with suspected botulism whose symptoms or signs (e.g., paralysis) are progressing should be treated with BAT regardless of the time that has elapsed since symptom onset.  Patients with suspected botulism whose symptoms and signs are not progressing and who have no remaining voluntary muscle function are less likely to benefit from antitoxin treatment, especially if >7 days have passed since symptom onset, because toxin is infrequently detected beyond this point of illness.[17]

Do not routinely perform skin testing for sensitivity before BAT administration.  Do not give patients with suspected botulism a second dose of BAT unless progression of paralysis clearly continues after the initial dose should have taken effect and suspicion for botulism is high.  If neurologic signs progress for >1 day after administration of one vial of BAT, consider diagnoses other than botulism.[17]



Medication Summary

The goals of pharmacotherapy are to reduce morbidity and prevent complications. Medication commonly used in the treatment of botulism is described below. In addition to that described, guanethidine and 4-aminopyridine have been used for the treatment of botulinum paralysis but have not been shown to be effective.

The use of local antibiotics such as penicillin G or metronidazole may be helpful in eradicating Clostridium botulinum in wound botulism. Antibiotic use is not recommended for infant botulism because cell death and lysis may result in the release of more toxin. Aminoglycoside antibiotics and tetracyclines, in particular, may increase the degree of neuromuscular blockade by impairing neuronal calcium entry.

Current research into pharmacotherapy has mainly focused on small molecules, peptides, and peptidomimetics that inhibit botulism neurotoxin light chain proteolytic activity. However, a few drug candidates have reached clinical evaluation. Potential new treatment targets include botulism neurotoxin uptake and processing inhibitors, enzymatic inhibitors, as well as modulators of neuronal processes associated with toxin clearance, neurotransmitter potentiation, and other pathways involved in neuronal recovery and repair.[18]

Antitoxin therapy

Class Summary

Therapy consists of antibodies against toxin types A, B, C, D, E, F, and G to neutralize serum toxin concentrations.

Botulinum antitoxin, heptavalent (HBAT)

Investigational antitoxin indicated for naturally occurring noninfant botulism. Equine-derived antitoxin that elicits passive antibody (ie, immediate immunity) against Clostridium botulinum toxins A, B, C, D, E, F, and G.

Each 20-mL vial contains equine-derived antibody to the 7 known botulinum toxin types (A through G) with the following nominal potency values: 7500 U anti-A, 5500 U anti-B, 5000 U anti-C, 1000 U anti-D, 8500 U anti-E, 5000 U anti-F, and 1000 U anti-G.

Available from CDC as treatment IND protocol. Replaces licensed bivalent botulinum antitoxin AB (BAT-AB) and investigational monovalent botulinum antitoxin E (BAT-E). To obtain, contact CDC Emergency Operations Center; telephone: (770) 488-7100.

Immune Globulin

Class Summary

Consists of administration of immunoglobulin pooled from serum or plasma of immunized subjects.

Botulism immune globulin IV

For infant botulism, IV Human Botulinum Immune Globulin (BIG-IV or BabyBIG) trials in California were completed in early 1997; trials demonstrated safety and efficacy of human-derived botulinum immune globulin and a reduced mean hospital stay from 5.5 wk to 2.5 wk.

BIG-IV is now FDA approved and is only available from the California Department of Health Services (24-h telephone: 510-540-2646).

Solvent-detergent treated and viral screened immune globulin is derived from pooled adult plasma from persons immunized with botulinum toxoid that developed high neutralizing antibody titers against botulinum neurotoxins type A and B. Indicated to treat infant botulism (age < 1 y) caused by type A or B C botulinum.